1,627 matches
-
GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331. 8. Burris HA, Moore MJ, Andersen J et al. Improvements în survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. 9. Cunningham D, Chau I, Stocken C et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine în patients with advanced pancreatic cancer. Eur J Cancer 2005; 3 (4 Suppl): 312. 10
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
benefit from gemcitabine-based combination chemotherapy applied în advanced pancreatic cancer. BMC Cancer 2008; 28: 8-82. 12. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone în patients with advanced pancreatic cancer: a phase III trial of the Național Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. 13. Rykowski JJ, Hilgier M. Efficacy of neurolytic celiac plexus block în varying locations of pancreatic cancer: influence on pain relief. Anesthesiology 2000; 92
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
a inclus pacienți cu ciroză hepatică Child-Pugh A a arătat o creșterea a supraviețuirii cu 2,8 pentru tratamentul cu sorafenib comparativ cu placebo [II, A] ceea ce face ca sorafenibul să reprezinte prima opțiune în ceea ce privește tratamentul sistemic ● includerea într-un trial clinic ● BSC ● Chimioterapia sistemică nu trebuie inclusă în standardul de tratament dar poate fi luată în discuție, în colaborare cu pacientul, dacă local nu sunt disponibile alte opțiuni terapeutice. Regimurile chimioterapice conținând antracicline au o rată de răspuns de 10
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87: 741-749. 2. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferonalpha on incidence of hepatocellular carcinoma în chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055. 3. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas în patients
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
et al. A randomized phase III study of doxorubicin vs cisplatin/interferonalpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97(20): 1532-1538. 18. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171. 19. Vogl T, Zangos S, Balzer J et al. Transarterial chemoembolization (TACE) în hepatocellular carcinoma: technique, indication and results. Rofo 2007; 179(11): 1113-1126. 20. Livraghi T, Bolondi
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-460. 2. Kapiteijn E, Marijnen CAM, Nagtegaal ID et al. Preoperative radiotherapy în combination with total mesorectal excision improves local control în resectable rectal cancer. Report from a multicenter randomized trial. For the Dutch Colo Rectal Cancer Group and other cooperative investigators. New Engl J Med 2001; 345: 638-646. 3. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Sauer R, Becker H, Hohenberger W et al. German Rectal Cancer Study Group Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740. 7. Folkesson J, Birgisson H, Pa° hlman L et al. Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-5650. 8. Bipat S, Glas AS, Slors FJ et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
2004; 232: 773-783. 9. Sebag-Montefiore-D for the NCRI colorectal cancer study group and CR0, Steele R, Quirke P et al. Routine short course pre-op radiotherapy or selective post-op chemotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. ASCO Ann Meeting Proc Part 1 2006; vol. 24: No 18S, abstr 3511. 10. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-term results of a randomised trial comparing preoperative short-course radiotherapy vs preoperative conventionally fractionated chemoradiation for rectal cancer
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
chemotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. ASCO Ann Meeting Proc Part 1 2006; vol. 24: No 18S, abstr 3511. 10. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-term results of a randomised trial comparing preoperative short-course radiotherapy vs preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223. 11. Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
examen CT al regiunii afectate după 2-3 luni de chimioterapie paliativă [IV]. Bibliografie 1. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047. 2. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment în advanced colorectal cancer. J ClinOncol 2000; 18: 2938-2947. 3. Tournigand C, Andre T, Achille E
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised phase III trials. Br J Cancer 2004; 90: 1190-1197. 5. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure în patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412. 8. Van Cutsem E, Nordlinger B, Adam R et al. Towards a pan-European consensus on the treatment of patients
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
2004; 351: 337-345. 16. Jonker D, O'Callaghan C, Karapetis C et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048. 17. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive carealone în patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664. 18. Amado RG, Wolf M, Peeters M, Van Cutsem E et al. Wild-type KRAS is required
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least în GIST. J Clin Oncol 2007; 25: 1760-1764. 2. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumours expressing KIT. J Clin Oncol 2008; 26: 620-625. 3. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumours expressing KIT. J Clin Oncol 2008; 26: 620-625. 3. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels în patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632. 4. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
stromal tumour (GIST). Cancer 2008; 112: 608-615. 7. DeMatteo RK, Owzar KR, Maki R et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) în patients with completely resected localized primary gastrointestinal stromal tumour (GIST): North American intergroup phase III trial ACOSOG Z9001. ASCO Annual Meetings Proceedings Part I. J Clin Oncol 2007; 25 (18 Suppl): 10079. 8. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib în patients with advanced gastrointestinal stromal tumour after failure
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Proceedings Part I. J Clin Oncol 2007; 25 (18 Suppl): 10079. 8. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib în patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338. 9. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate în advanced gastrointestinal stromal tumours. N Engl J Med 2002; 347: 472-480. 10. Eisenberg BL, Harris J, Blanke CD et
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
1329-1338. 9. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate în advanced gastrointestinal stromal tumours. N Engl J Med 2002; 347: 472-480. 10. Eisenberg BL, Harris J, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumour (GIST): Early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2008 Oct 21 [Epub ahead of print]. 11. Fletcher CDM, Berman JJ, Corless
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Organizațion for Research and Treatment of Cancer - Italian Sarcoma Group - Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-5804. 16. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival în gastrointestinal stromal tumours with high-dose imatininb: randomized trial. Lancet 2004; 364: 1127-1134. 17. Zalcberg JR, Verveij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
D et al. French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery în resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-253. 6. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy în patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360. 7. Winton T, Livingston R, Johnson D et al. Național Cancer Institute of Canada Clinical Trials Group; Național Cancer Institute
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360. 7. Winton T, Livingston R, Johnson D et al. Național Cancer Institute of Canada Clinical Trials Group; Național Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation în resected non-small-cell lung cancer. N Engl J Med. 352. 2005; 2589-2597. 8. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation în patients with completely resected stage
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
J Med. 352. 2005; 2589-2597. 8. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation în patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27. Erratum în: Lancet Oncol. 2006 7:797. 9. Burdett S. Stewart L on behalf of the PORT Meta-analysis Group. Postoperative radiotherapy în non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Burdett S. Stewart L on behalf of the PORT Meta-analysis Group. Postoperative radiotherapy în non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005; 47: 81-83. 10. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care în patients with non-small cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000; 18: 2095-2103. 11. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
al. Prospective randomized trial of docetaxel versus best supportive care în patients with non-small cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000; 18: 2095-2103. 11. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel în patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597. 12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Național Cancer Institute of Canada Clinical Trials Group. Erlotinib în
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
bevacizumab as firstline therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol 2009; 27: 1227-1234. 17. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy în patients with nonsmallcell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009; 373: 15251531. Cancerul pulmonar microcelular Recomandările ESMO pentru diagnosticare, tratament și monitorizare M. Sorensen*1) amp; E. Felip*2) *1) Department of Oncology, Unit for Experimental Cancer Treatment, Rigshospitalet, Copenhagen, Denmark; *2) Medical Oncology Service, Vall d'Hebron
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Lung Cancer. J Thorac Oncol 2007; 3: 1067-1077. 2. Sundstrom S, Bremnes RM, Kaasas S et al. Cisplatin and etoposide regimen is superior to cyclophosphanide, epirubicin, and vincristine regimen în small cell lung cancer: results form a randomized phase III trial with 5 years' follow-up.J Clin Oncol 2002; 20: 4665-4672. 3. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin în the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin containing regimen
EUR-Lex () [Corola-website/Law/227406_a_228735]